Association for Human Pharmacology in the Pharmaceutical Industry Christmas Lecture

Event Date:
15 December 2020, 14:00 – 16:30 (GMT)
Location:
Virtual Meeting
View ProgramView Program

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) is a membership organisation for professionals working within early drug development. The annual Christmas Lectures provide an opportunity for members to learn from industry experts and peers.

This year’s lectures will include a presentation by Richmond Pharmacology’s CEO and Founder, Jorg Taubel M.D.

Throughout 2020, Richmond Pharmacology quickly adapted recruitment and operational processes to safeguard research participants, staff and visitors to the London-based clinical research unit. Dr Taubel will share the new operating model for the COVID-secure facility and share lessons learned during this process.  

To attend the Christmas Lectures, please register here: https://cconline.eventsair.com/ahppi/ahppi2020/Site/Register

A summary of discussions of the 2019 annual meeting, which focused on impending change, innovation and future challenges, has been published. Read more in Frontiers in Pharmacology.


Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more